The study is taking place at the Center for Vaccinology (CEVAC) at Ghent University Hospital. OVX836 is a first-in-class influenza A vaccine candidate that targets the nucleoprotein (NP), a highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback